cefazolin + vancomycin (The London Spine Centre)

The antibiotic regimen associated with The London Spine Centre's PARISS (Prolonged Antibiotics in Spine Surgery) trial consists of either cefazolin or vancomycin administered for postoperative infection prophylaxis. Cefazolin is a first-generation cephalosporin that acts by inhibiting bacterial cell wall synthesis through the binding and inactivation of penicillin-binding proteins (PBPs). Vancomycin is a glycopeptide antibiotic that inhibits cell wall synthesis by binding to the D-alanyl-D-alanine C-terminus of peptidoglycan precursors, thereby blocking the polymerization of the bacterial cell wall. The Phase 4 trial specifically evaluates the efficacy of a standard 24-hour postoperative antibiotic course versus a prolonged 72-hour course (or until 24 hours after drain removal) in reducing the incidence of complicated surgical site infections in patients undergoing posterior spine surgery requiring Hemovac drains.

Other names

PARISS trial antibioticscefazolinvancomycin